Pre-financing and operational set-up of the company was achieved with the support of the State of Rheinland-Palatinate (Rheinland-Pfalz), and the University of Mainz. Financing was obtained in three rounds from Hightech-Gründer Fonds (HTGF), FIB and WFT funds of the ISB, the KfW, with EVP Capital Management AGs managing the RPF investment and acting as the lead investor.
EVP Capital Management AG
EVP Capital Management AG, formerly equinet Venture Partners AG, was established in 2008 through the MBO of the two partners Dr. Thomas Hoch and Dr. Farsin Yadegardjam. With a total fund volume of close to one hundred million EURO EVP Capital invests in fast-growing technology companies in the ITC and life sciences fields. The current life science portfolio includes GENEART AG and Nanogate AG, both listed in Frankfurt, as well as EUROIMMUN AG, Galantos Pharmaceuticals GmbH, Phenex Pharmaceuticals AG and Signature Diagnostics AG. Further information is available at http://www.evp-capital.com/.
KfW Mittelstandsbank supports founders, self employed professionals, inventors and medium size companies by means of classical loans, investments and mezzanine financings and provides them with professional advice. In 2006, the total capital invested amounted to EUR 12.6 billion.
KfW Mittelstandsbank invests in early stage and later stage companies. It offers tailored and transparent financing opportunities to start-up and technology focused companies (TU) as well as established medium-size companies.
High-Tech Gründerfonds (HTGF)
HTGF invests venture capital into newly founded technology ventures with high development potential which leverage promising research results. It provides seed financing of up to EUR 500,000 to support the research and development of a prototype or to obtain a proof-of-principle, which will justify further investment or enable market entrance. It is expected that a side investment of 20% (10% in the former East Germany) of the funds provided by the HTGF is co-invested by the founders or another investor. Through its investment, HTGF gains 15% of the shares of its portfolio companies. The HTGF is a result of the initiative "Partners for Innovation" with total assets of EUR 272 million. Investors of the "public-private partnerships" are the German Minister for Economy and Technology, the KfW Bank group as well as six industry partners: BASF, Deutsche Telekom, Siemens, DaimlerChrysler, Robert Bosch und Carl Zeiss.
FIB Fonds for Innovation and Employment in Rheinland-Pfalz
FIB is a spin-off from the Investitions- und Strukturbank Rheinland-Pfalz (ISB) GmbH, the central institution for the advancement of the economy of the State of Rheinland-Pfalz, and the KfW.
FIB supports small to medium-size companies in Rheinland-Pfalz in the financing of technology-focused or employment-enhancing endeavours through investments at favorable conditions. Co-investments in collaboration with other instruments of the ISB are possible, enabling financing as a one-stop-shop using instruments like grants, guaranties, favorable loans and the support for finding suitable vesting and additional investments in a timely manner.
WFT Venture Capital Rheinland-Pfalz
WFT – an associated company from the Investitions- und Strukturbank Rheinland-Pfalz (ISB) GmbH – offers venture capital for attractive conditions and affords new founded companies the development and placement of innovative products and production processes by enlargement of representing liable capital base.
Additional Funding and Future Requirements
As spin-off of an academic institute aiming to commercialize some of the ideas and techniques developed in the former environment, the investment fonds participating so far in the financing of Galantos Pharma all were local or national seed funds and funding agencies.
Rhineland-Palatinate Innovation Fund
Our company was financed with equity capital of the Rhineland-Palatinate Innovation Fund. This fund provides young, technology-oriented companies in Rhineland-Palatinate venture capital available. Thus, the capital of the Company's financial condition improved and created a successful startup technology companies. The capital of Rhineland-Palatinate Innovation Fund was endowed with funds from the European Regional Development Fund (ERDF) and national co-financing.
Federal Ministry for Research and Development, Biochance II Program
Galantos Pharma lead a Joint Research Initiative of several academic laboratories and small companies aimed at developing novel neuroprotective drugs for the treatment of Alzheimer's disease. This research program was supported by grants from the Federal Ministry for Research and Development (BMBF).